Patiromer is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. It is available as powder for oral suspension. MedsAcross supplies Patiromer for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. Veltassa is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
Source: US FDA prescribing information
Veltassa is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.
Source: US FDA prescribing information
For adults, the recommended starting dose of Veltassa is 8.4 grams administered orally once daily. For adults, adjust dose by 8.4 grams daily as needed at one-week intervals to obtain desired serum potassium target range. For pediatric patients 12 to 17 years of age, the recommended starting dose of Veltassa is 4 grams administered orally once daily. For pediatric patients 12 to 17 years of age, adjust dose by 4 grams daily as needed at one-week intervals to obtain desired serum potassium target range. The maximum recommended dosage in adults and pediatric patients older than 12 years is 25.2 grams once daily.
Source: US FDA prescribing information
Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components. Known hypersensitivity to Veltassa or any of its components.
Source: US FDA prescribing information
Worsening of Gastrointestinal Motility. Hypomagnesemia. Worsening of Gastrointestinal Motility Avoid use of Veltassa in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in the clinical studies.
Source: US FDA prescribing information
The following adverse reaction is discussed in greater detail elsewhere in the label: Hypomagnesemia Most common adverse reactions (incidence ≥ 2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence.
Source: US FDA prescribing information
Veltassa has the potential to bind some oral co-administered medications, which could decrease their gastrointestinal absorption. Binding of Veltassa to other oral medications not listed in Table 3 below could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time Veltassa is administered. Administer other oral medications at least 3 hours before or 3 hours after Veltassa. Take other orally administered drugs at least 3 hours before or 3 hours after Veltassa except those shown to not have a clinically important interaction.
Source: US FDA prescribing information
Storage Veltassa should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). If stored at room temperature (25°C ± 2°C [77°F ± 4°F]), Veltassa must be used within 3 months of being taken out of the refrigerator. Avoid exposure to excessive heat above 40°C (104°F). For either storage condition, do not use Veltassa after the expiration date printed on the packet.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Patiromer, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Veltassa 8.4 g powder for oral suspensionOral Cold chain | Vifor Pharma | US FDA | Available on request |
| Veltassa 1 g powder for oral suspensionOral Cold chain | Vifor Pharma | US FDA | Available on request |
| Veltassa 16.8 g powder for oral suspensionOral Cold chain | Vifor Pharma | US FDA | Available on request |
| Veltassa 25.2 g powder for oral suspensionOral Cold chain | Vifor Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Patiromer in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Patiromer and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Patiromer, including Veltassa.
Yes. Patiromer has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Patiromer must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Patiromer is classified under ATC code V03AE09 (Patiromer).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.